Clinical Pharmacology Drug Development Immunity Vaccines 
Pharmaceutical Business Review
AUGUST 28, 2023
These candidates are being developed to offer better protection, extend the duration in preventing illness and transmission, as compared to the current vaccine technologies. As part of the contract, Allucent will initiate a Phase IIb clinical trial of 10,000 participants under BARDA’s Clinical Studies Network.
pharmaphorum
NOVEMBER 4, 2020
The picture is hardly more promising for vaccines: the number of approaches, difficulty in finding patients in which to carry out pivotal trials, irrelevant choice of endpoints … the outlook is far from promising. The M&S approach should be integrative, from the molecular level to the clinical and population outcomes.
Expert insights. Personalized for you.
52 
Let's personalize your content